IEHP UM Subcommittee Approved Authorization Guideline

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Guideline #</th>
<th>Original Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genicular Nerve Neurotomy</td>
<td>UM_NEU 02</td>
<td>5/11/2016</td>
</tr>
<tr>
<td>Section</td>
<td>Neurology</td>
<td>Revision Date</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1/09/19</td>
</tr>
</tbody>
</table>

COVERAGE POLICY
Based on a review of the currently available literature, there is insufficient evidence to support the use of Genicular Nerve Neurotomy in the treatment of chronic knee pain due to Osteoarthritis.

COVERAGE LIMITATIONS AND EXCLUSIONS
Non-covered CPT Codes:
64640, 64999

ADDITIONAL INFORMATION
Genicular Nerve Neurotomy is a treatment of chronic knee pain due to osteoarthritis. Pain signals are found to arise from the genicular nerves, sensory nerve branches of the tibial, common peroneal and obturator nerves which supply the capsule of the knee joint and intra-articular and extra-articular ligaments. A diagnostic genicular nerve block is first done. If there is sufficient pain relief in the knee, a Genicular Nerve Neurotomy is performed to alleviate the knee pain, thereby restoring function.

A search of the peer-reviewed medical literature demonstrated that there is a lack of adequately designed trials concerning the use of this modality in the treatment of chronic knee pain due to osteoarthritis.

CLINICAL/REGULATORY RESOURCE
MEDICARE:
Medicare does not have a National Coverage Determination (NCD) or a Local Coverage Determination (LCD) for California regarding the use of Genicular Nerve Neurotomy for the treatment of chronic knee pain due to Osteoarthritis.

MEDI-CAL:
There are no relevant Medi-Cal guidelines or policy statements regarding the use of Genicular Nerve Neurotomy for the treatment of chronic knee pain due to Osteoarthritis.
**MCG REVIEW CRITERIA:**
No guidelines pertaining to the use of genicular nerve neurotomy for treatment of chronic knee pain were noted in a search of MCG review criteria.

**APOLLO MEDICAL REVIEW CRITERIA GUIDELINES FOR MANAGING CARE:**
There is no discussion of the use of Genicular Nerve Neurotomy for the treatment of chronic knee pain due to Osteoarthritis.

**BLUE SHIELD:**
Blue Shield of California states, “Radiofrequency ablation of peripheral nerves to treat pain associated with…knee osteoarthritis is considered investigational.”

**DEFINITION OF TERMS**
- **Ablation:** the removal or destruction of a body part or tissue or its function. Ablation may be performed by surgery, hormones, drugs, radiofrequency, heat or other methods.
- **Denervation:** also known as ablation.
- **Genicular Nerve:** Sensory nerve arising from branches of the tibial, common peroneal and obturator nerves. The tibial and common peroneal nerve arise from the sciatic nerve, while the obturator nerve arises from the anterior division of the L2-L4 spinal nerves.
- **Neurotomy:** the destruction of nerves or nerve tissue by heat, cutting or by chemical injection.
- **Percutaneous:** a medical procedure where access to tissue is done via a needle puncture of the skin.
- **Radiofrequency:** an invasive procedure that involves heating tissue in order to destroy it.
- **Thermocoagulation:** also known as ablation, or denervation.

**REFERENCES**
DISCLAIMER

IEHP Clinical Authorization Guidelines (CAG) are developed to assist in administering plan benefits, they do not constitute a description of plan benefits. The Clinical Authorization Guidelines (CAG) express IEHP's determination of whether certain services or supplies are medically necessary, experimental and investigational, or cosmetic. IEHP has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). IEHP makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in the Clinical Authorization Guidelines (CAG). IEHP expressly and solely reserves the right to revise the Clinical Authorization Guidelines (CAG), as clinical information changes.